Room: Osceola Ballroom C
During the last two decades, there have been numerous publications on the applications of EPID for both machine QA, pre-treatment IMRT QA, and in vivo dosimetry. There is interest in how fully automated, EPID-based QA methods may bring efficiencies to clinical programs and support quality and safety. While some institutions have developed in-house solutions to integrate EPIDs into their machine QA program, the lack of commercially available solutions has hindered adoption by other clinics. Fewer clinics have integrated the use of EPIDs as an in-vivo tool. Additional barriers include defining which tests from AAPM reports TG 142 and MPPG 8a are suitable for routine evaluation with an EPID, how to define action levels, and how to confirm problems identified from EPID QA data. Advantages of EPID-based machine QA include improvements in the efficiency, standardization and documentation of input and output, and leveraging automation to further streamline QA tests. The course will present applications of EPIDs for automation of machine quality assurance along with the benefits and potential risks. The critical role of complementary non-EPID technology to ensure adequate performance will also be discussed. The unique strengths of EPIDs for in vivo applications will also be presented.
1. To recognize the current and future role of EPIDs, including automation, for machine and pre-treatment IMRT QA in radiation oncology.
2. To understand practical considerations in implementing automation EPID QA and how to best incorporate these techniques as part of a comprehensive QA program.
3. To understand the benefits and risk associated with patient specific quality assurance when performing EPID QA pre-treatment and in-vivo.
Funding Support, Disclosures, and Conflict of Interest: Jean Moran: Varian Medical Systems Grant Casey Bojechko: UCSD grant